SCHEMBL17399990

SCHEMBL17399990

COC(=O)c1ccc2c(c1)-c1c(C)cc(OCCCS(C)(=O)=O)cc1CC(C)(C)O2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.44
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
FFAR1 O14842 13/20 0.38
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 3/20 0.38
GAA P10253 3/20 0.38
HPGD P15428 2/20 0.38
CASP1 P29466 2/20 0.38
HSD17B10 Q99714 2/20 0.38
GLA P06280 1/20 0.38
CASP7 P55210 1/20 0.38
MAPK1 P28482 1/20 0.38
GNA15 P30679 1/20 0.37
SLC10A1 Q14973 1/20 0.37
ABCC2 Q92887 1/20 0.37
SLCO1B3 Q9NPD5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17385978 0.86 KDM4E (0.41) MAPTLMNATSHRRAB9ASMN1; SMN2
SCHEMBL17386353 0.86 MAPT (0.45) MAPTLMNATSHRRAB9ASMN1; SMN2
SCHEMBL17429658 0.85 FFAR1 (0.42) LMNATSHRFFAR1ALDH1A1MAPK1
SCHEMBL17400091 0.84 FFAR1 (0.41) LMNARAB9ASMN1; SMN2FFAR1KDM4E
SCHEMBL17385947 0.84 FFAR1 (0.41) LMNATSHRFFAR1ALDH1A1MAPK1
SCHEMBL17385818 0.82 FFAR1 (0.43) MAPTFFAR1
SCHEMBL17429688 0.81 CYP1A2 (0.43) MAPTLMNATSHRRAB9ASMN1; SMN2
SCHEMBL17386274 0.81 FFAR1 (0.40) FFAR1GNA15SLC10A1ABCC2SLCO1B3
SCHEMBL17418097 0.80 FFAR1 (0.41) MAPTFFAR1KDM4E
SCHEMBL17386054 0.80 MAPT (0.45) MAPTLMNATSHRRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9643946-B2 Tricyclic compound and use thereof SK CHEMICALS CO., LTD. (KR) 2017-05-09 US disclosed
US-9643946-B2 Tricyclic compound and use thereof SK CHEMICALS CO., LTD. (KR) 2017-05-09 US disclosed
US-9643946-B2 Tricyclic compound and use thereof SK CHEMICALS CO., LTD. (KR) 2017-05-09 US disclosed
US-20160009677-A1 TRICYCLIC COMPOUND AND USE THEREOF SK CHEMICALS CO., LTD. (KR) 2016-01-14 US disclosed
US-20160009677-A1 TRICYCLIC COMPOUND AND USE THEREOF SK CHEMICALS CO., LTD. (KR) 2016-01-14 US disclosed
EP-2963027-A1 TRICYCLIC COMPOUND AND USE THEREOF SK Chemicals Co., Ltd. (KR) 2016-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009677-A1 TRICYCLIC COMPOUND AND USE THEREOF GPR65, GPR119, GPR35 MAPT 2131/4885LMNA 2845/4885TSHR 1867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.